The healthcare sector stands out for its vast quantities of data, often stored across numerous separate silos.
Hundreds of millions of patient records are housed within various electronic health records (EHRs) managed by providers like Epic, Cerner, and Athena. Additionally, insurance firms hold extensive data collections on coverage, reimbursement rates, and patient demographics. Pharmacies and laboratories further enrich these data sets with information on medication utilisation and diagnostic outcomes.
Over the last decade, several companies have attempted to consolidate patient information across different health systems and care environments. In recent years, however, San Francisco-based Innovaccer has emerged as a frontrunner in this domain, according to various investors.
Currently, Innovaccer serves six of the top ten healthcare systems in the U.S. and is making significant progress in marketing its platform to insurers, pharmaceuticals, and governmental entities.
The company offers a comprehensive suite of applications tailored for value-based care, population health management, and customer relationship management (CRM), all based on its cloud-enabled architecture.
To expand its capabilities, Innovaccer plans to launch several AI co-pilots and agents, including an AI medical scribe, a tool for streamlining prior authorisation processes, and an additional resource for managing denied insurance claims.
In support of its ambitious goal to become what co-founder and CEO Abhinav Shashank describes as “a one-stop shop for healthcare AI solutions,” the company has successfully secured a $275 million Series F funding round. This investment comes from notable contributors, including B Capital Group, Banner Health, Danaher Ventures, Generation IM, Kaiser Permanente, and M12.
This funding round consists of both primary and secondary financing; approximately 35% of the funds will be used to provide liquidity to the company’s seed and Series A investors, as noted by Shashank. Despite this secondary allocation, there remains substantial capital available for Innovaccer’s next phase of expansion.
While the company opted not to disclose its current valuation, sources familiar with the transaction suggested that the post-money valuation from the primary funding stands at roughly $3.45 billion. This marks a slight increase from the $3.2 billion valuation Innovaccer achieved following its previous $150 million funding round in late 2021, at a time when the pandemic was still driving favourable conditions. The valuation from the secondary transaction was likely lower, though specific numbers were not disclosed.
This fundraising validates a previous report by StartupSuperb from last May regarding Innovaccer’s discussions to secure $250 million, with Kaiser Permanente positioned as a leading investor.
The Fabric of Healthcare Data
Founded in 2014, Innovaccer aimed to unify data across various sectors. However, after three years, the focus shifted solely to the healthcare industry.
“Healthcare operated in a pre-Internet environment, lacking a connected information fabric,” Shashank explained to StartupSuperb.
To address this, Innovaccer embarked on creating robust data infrastructure by integrating its platform with every major EHR system. Shashank mentioned that the company invested around two years and over $100 million to establish these connections.
This commitment appears to be fruitful. Over the last five years, Innovaccer’s revenue has grown by 50% annually, and the company is projected to reach $250 million in annual recurring revenue (ARR) this year.
Shashank mentioned that although Innovaccer is contemplating an initial public offering (IPO), the company will only pursue this if it achieves an annual revenue between $400 million and $500 million.
Presently, the company is concentrated on developing a platform dedicated to AI applications built on its foundational layer. Shashank aspires for customers to select Innovaccer as their primary provider for all AI requirements instead of sourcing tools from multiple providers.
This vision has resonated well with investors. Rashmi Gopinath, who initially invested in Innovaccer during her tenure as a managing director at M12 and is now a co-founder and managing partner at BAM Corner Point (which also invests in Innovaccer), commended the company’s proactive approach to integrating AI solutions.
“I believe that the rapid advancements in generative AI will serve as a significant catalyst for the company’s momentum,” she noted.
Innovaccer intends to develop some AI solutions internally while also collaborating with or acquiring other promising AI technologies.
Shashank expressed confidence that if Innovaccer successfully realises its vision, it has the potential to become the largest healthcare enterprise within the next five years. “Fingers crossed,” he added.
